source
- Why pediatric rare oncology outperforms in a volatile biotech marketReal progress happens where unmet medical need is greatest and patient impact can be clearly measured. Pediatric rare cancers exemplify these criteria and have therefore generated continued investm…BioSpace · 9m ago↗ source
- Moderna shares surge as Merck-Moderna mRNA melanoma vaccine meets Phase 3 endpointMerck and Moderna reported that their personalized mRNA cancer vaccine, combined with Merck’s Keytruda, slowed melanoma recurrence in a Phase 3 study. The interim analysis showed a statistically si…